ReviewTheranostics2021
Cancer photo-immunotherapy: from bench to bedside.
Review in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 87 citations in OpenAlex.
- Smart drug delivery systems for immunotherapeutic agents: focus on biological/biogenic platform-based intelligent delivery in cancer immunotherapy.Drug delivery and translational research · 2026Review
- Listening to Immunotherapy - Ultrasound and Photoacoustic Imaging Strategies to Guide and Enhance Cancer Treatments.Molecular imaging and biology · 2026Review
- Immunological Significance of the ICI-PIT-ICI Sequence in Recurrent Oral Cancer: A Narrative Review with Illustrative Cases.Diagnostics (Basel, Switzerland) · 2026Review
- Recent Advances in Nanomedicine for Targeted Phototherapy in Head and Neck Cancer.International journal of nanomedicine · 2026Review
- Non-surgical Synergistic Interventions for the Treatment of Skin Cancer.Current pharmaceutical design · 2026Review
- Multifunctional Biomedical Devices with Closed-Loop Systems for Precision Therapy.Advanced healthcare materials · 2025Review
- Synergy between photonics and biological approaches-A review of combination therapies for cancer theranostics.APL bioengineering · 2025Review
- Metal nanoparticles in cancer theranostics: from synthesis to tumor microenvironment-responsive applications.Drug delivery · 2025Review
- Article
- Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Phototherapy in cancer treatment: strategies and challenges.Signal transduction and targeted therapy · 2025Review
- Multimodal Key Anti-Oncolytic Therapeutics Are Effective In Cancer Treatment?International journal of nanomedicine · 2025Review
- Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study.Frontiers in immunology · 2025Article
- Illuminating Hope for Tumors: The Progress of Light-Activated Nanomaterials in Skin Cancer.International journal of nanomedicine · 2025Review
- Localized ablative immunotherapy enhances antitumor immunity by modulating the transcriptome of tumor-infiltrating Gamma delta T cells.Cancer letters · 2024Article
- Stable triangle: nanomedicine-based synergistic application of phototherapy and immunotherapy for tumor treatment.Journal of nanobiotechnology · 2024Review
- Bioluminescent Systems for Theranostic Applications.International journal of molecular sciences · 2024Review
- A relay-type innate immunity activation strategy involving water-soluble NIR-II AIEgen for boosted tumor photo-immunotherapy.Theranostics · 2024Article
- Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis.Molecular cancer · 2023Review
- Immuno-photodynamic Therapy (IPDT): Organic Photosensitizers and Their Application in Cancer Ablation.JACS Au · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
Targeted therapy and immunotherapy in combination is considered the ideal strategy for treating metastatic cancer, as it can eliminate the primary tumors and induce host immunity to control distant metastases. Phototherapy, a promising targeted therapy, eradicates primary tumors using an appropriate dosage of focal light irradiation, while initiating antitumor immune responses through induced immunogenic tumor cell death. Recently, phototherapy has been employed to improve the efficacy of immunotherapies such as chimeric antigen receptor T-cell therapy and immune checkpoint inhibitors. Phototherapy and immunoadjuvant therapy have been used in combination clinically, wherein the induced immunogenic cell death and enhanced antigen presentation synergy, inducing a systemic antitumor immune response to control residual tumor cells at the treatment site and distant metastases. This review summarizes studies on photo-immunotherapy, the combination of phototherapy and immunotherapy, especially focusing on the development and progress of this unique combination from a benchtop project to a promising clinical therapy for metastatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.